Candidate Selection
IND Enabling Studies
Phase 1
Phase 2
Phase 31
Upcoming
Milestones
(ROS1/TRK)
Repotrectinib
ROS1+ advanced NSCLC in TKI-naïve patients
ROS1+ advanced NSCLC in platinum based chemo- and TKI-pretreated patients
NTRK+ advanced solid tumors in TKI-naïve patients
NTRK+ advanced solid tumors in TKI-pretreated patients
TRIDENT-1
Registrational
cohorts
Current Phase
Phase 1
TRIDENT-1
Registrational
cohorts
Initiated registrational Phase 2 portion in 2H 2019
ROS1+ advanced NSCLC TKI-pretreated w/o prior chemo
Current Phase
Phase 1
Non-registrational cohort of TRIDENT-1
Repotrectinib in pediatric advanced solid tumors
Current Phase
IND Enabling Studies
Initiated trial in 2H 2019
Repotrectinib combinations
Current Phase
IND Enabling Studies
Trial design in development
(MET/CSF1R/SRC)
TPX-0022
MET+ advanced solid tumor patients
Current Phase
Phase 1
Initiated trial in 2H 2019
(RET/SRC)
TPX-0046
RET+ advanced solid tumor patients
Current Phase
IND Enabling Studies
Initiated trial in 2H 2019
(ALK)
TPX-0131
ALK+ advanced NSCLC
- Not required for Phase 2 registrational clinical trials